Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.

In the phase 3 trial, nemolizumab monotherapy showed rapid and sustained improvements in key signs (skin lesions) and ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

CAN10 is designed to inhibit the pro-inflammatory cytokines through its action on the interleukin-1 receptor accessory ...

Could interleukin-1 antagonists be the answer to managing acute gout? Guidelines for the management of this disorder, issued by the European League Against Rheumatism (EULAR) and the British ...

For instance, signaling from the interferon (IFN) receptors, interleukin-4 (IL-4) receptor and gp130 (a common component of receptors for the IL-6 family of cytokines) is transduced by STAT1 ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).